chartexchange

MLTX Stock Climbs On Optimism Ahead Of FDA Acceptance Deadline For Lead Drug Filing

Stocktwits | Nov 11, 2026 5:50 PM EST

MoonLake is developing Sonelokimab primarily for hidradenitis suppurativa (HS), a chronic inflammatory skin condition with limited effective treatments.

Read original article